CN117586400A - 结合4-1bb的抗体及其用途 - Google Patents

结合4-1bb的抗体及其用途 Download PDF

Info

Publication number
CN117586400A
CN117586400A CN202311290309.4A CN202311290309A CN117586400A CN 117586400 A CN117586400 A CN 117586400A CN 202311290309 A CN202311290309 A CN 202311290309A CN 117586400 A CN117586400 A CN 117586400A
Authority
CN
China
Prior art keywords
seq
antibody
chain variable
variable region
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202311290309.4A
Other languages
English (en)
Chinese (zh)
Inventor
康小强
黄潇
孙建明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Wei Li Zhi Bo Biotechnology Co ltd
Original Assignee
Nanjing Wei Li Zhi Bo Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Wei Li Zhi Bo Biotechnology Co ltd filed Critical Nanjing Wei Li Zhi Bo Biotechnology Co ltd
Publication of CN117586400A publication Critical patent/CN117586400A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202311290309.4A 2019-10-11 2020-09-30 结合4-1bb的抗体及其用途 Pending CN117586400A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962913744P 2019-10-11 2019-10-11
US62/913,744 2019-10-11
PCT/CN2020/119388 WO2021068841A1 (en) 2019-10-11 2020-09-30 Antibodies binding 4-1bb and uses thereof
CN202080071050.2A CN114555638B (zh) 2019-10-11 2020-09-30 结合4-1bb的抗体及其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080071050.2A Division CN114555638B (zh) 2019-10-11 2020-09-30 结合4-1bb的抗体及其用途

Publications (1)

Publication Number Publication Date
CN117586400A true CN117586400A (zh) 2024-02-23

Family

ID=75382666

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202311290309.4A Pending CN117586400A (zh) 2019-10-11 2020-09-30 结合4-1bb的抗体及其用途
CN202080071050.2A Active CN114555638B (zh) 2019-10-11 2020-09-30 结合4-1bb的抗体及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080071050.2A Active CN114555638B (zh) 2019-10-11 2020-09-30 结合4-1bb的抗体及其用途

Country Status (5)

Country Link
US (2) US11466086B2 (https=)
EP (1) EP4041772A4 (https=)
JP (2) JP7634001B2 (https=)
CN (2) CN117586400A (https=)
WO (1) WO2021068841A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11466086B2 (en) * 2019-10-11 2022-10-11 Nanjing Leads Biolabs Co., Ltd. Antibodies binding 4-1BB and uses thereof
CN118684772A (zh) * 2021-09-09 2024-09-24 广东东阳光药业股份有限公司 抗4-1bb的激动型抗体及其应用
WO2023168547A1 (en) * 2022-03-07 2023-09-14 Adagene Pte. Ltd. Anti-cd137 antibodies and methods of making and using the same
EP4584300A1 (en) * 2022-09-06 2025-07-16 TJ Biopharma (Shanghai) Co., Ltd. Multispecific constructs and uses thereof
JP2026508244A (ja) 2023-02-22 2026-03-10 ナンジング リーズ バイオラブズ シーオー．， エルティーディー． 抗Ｎｅｃｔｉｎ－４抗体及びそれを含む多重特異性抗体
WO2025067330A1 (zh) * 2023-09-27 2025-04-03 南京维立志博生物科技股份有限公司 用于治疗肿瘤的抗pd-l1和抗4-1bb双特异性抗体
CN117736330B (zh) * 2024-01-24 2024-05-17 上海沙砾生物科技有限公司 肿瘤坏死因子超家族受体9的特异性抗原结合蛋白及其应用
WO2026061538A1 (zh) * 2024-09-23 2026-03-26 南京维立志博生物科技股份有限公司 用于治疗恶性肿瘤的抗pd-l1和抗4-1bb双特异性抗体及其药物组合

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
TW201632559A (zh) 2015-02-22 2016-09-16 索倫多醫療公司 結合ｃｄ１３７之抗體治療劑
JP2018520650A (ja) * 2015-05-21 2018-08-02 アリゲーター・バイオサイエンス・アーベー 新規のポリペプチド
KR20180096789A (ko) 2016-01-11 2018-08-29 인히브릭스, 인크. 다가 및 다중특이적 41bb-결합 융합 단백질
WO2018045110A1 (en) * 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
BR112019005895A2 (pt) * 2016-09-23 2019-06-11 Merus N.V. moléculas de ligação que modulam uma atividade biológica expressa por uma célula
IL268836B2 (en) * 2017-02-24 2024-04-01 Macrogenics Inc Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11202000198QA (en) * 2017-08-04 2020-02-27 Genmab As Binding agents binding to pd-l1 and cd137 and use thereof
CN111194323B (zh) 2017-10-10 2024-07-09 努玛治疗有限公司 多特异性抗体
EP3470426A1 (en) * 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
TWI701259B (zh) 2017-11-09 2020-08-11 大陸商上海懷越生物科技有限公司 ４﹘１ｂｂ抗體及其製備方法和應用
CA3100119A1 (en) 2018-07-31 2020-02-06 Pieris Pharmaceuticals Gmbh Fusion protein specific for cd137 and pd-l1
CN109021107B (zh) 2018-09-05 2020-08-28 江苏诺迈博生物医药科技有限公司 一种特异性结合人pd-l1的单克隆抗体及包含其的药物和试剂盒
CN119798453A (zh) 2018-11-13 2025-04-11 Jn生物科学有限责任公司 激活免疫细胞的双特异性抗体
CN113286825B (zh) 2018-11-30 2024-06-18 爱必乐生物公司 抗pd-l1/抗4-1bb双特异性抗体及其用途
US11466086B2 (en) * 2019-10-11 2022-10-11 Nanjing Leads Biolabs Co., Ltd. Antibodies binding 4-1BB and uses thereof

Also Published As

Publication number Publication date
US20230192862A1 (en) 2023-06-22
JP2025069432A (ja) 2025-04-30
JP7634001B2 (ja) 2025-02-20
CN114555638B (zh) 2023-08-22
WO2021068841A1 (en) 2021-04-15
CN114555638A (zh) 2022-05-27
US20210107982A1 (en) 2021-04-15
EP4041772A4 (en) 2024-04-24
US11466086B2 (en) 2022-10-11
EP4041772A1 (en) 2022-08-17
JP2022553922A (ja) 2022-12-27

Similar Documents

Publication Publication Date Title
CN114555638B (zh) 结合4-1bb的抗体及其用途
CN111699199A (zh) 结合ox40的抗体及其用途
US10577424B1 (en) Antibodies binding VISTA and uses thereof
JP7505148B2 (ja) Ｌａｇ３に結合する抗体およびその使用
JP2023515223A (ja) Ｉｌ４ｒに結合する抗体とその使用
CN112236455B (zh) 结合pd-1的抗体及其用途
TWI851885B (zh) 結合cd40的抗體及其用途
JP2023518153A (ja) 抗体結合Ｓｉｇｌｅｃ１５及びその使用
CN115466327B (zh) 结合tigit的抗体及其用途
EP4438055A1 (en) Anti-siglec-15 antibody and use thereof
JP7571348B2 (ja) Ｐｄ－１結合抗体及びその用途
JP7440724B2 (ja) Ｃｔｌａ４に結合する抗体及びその使用
HK40066858B (zh) 结合4-1bb的抗体及其用途
HK40066858A (zh) 结合4-1bb的抗体及其用途
JP2023526294A (ja) Ｉｌ６ｒに結合する抗体及びその使用
HK40045182B (en) Antibody binding pd-1 and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: China

Address after: 210031 building 05, accelerator phase IV, No. 122, Huakang Road, Jiangbei new area, Nanjing, Jiangsu Province

Applicant after: Nanjing Weilizibo Biotechnology Co.,Ltd.

Address before: Room 711, 7th Floor, Building 3, No. 18 Jialing Jiangdong Street, Jianye District, Nanjing City, Jiangsu Province

Applicant before: NANJING WEI LI ZHI BO BIOTECHNOLOGY Co.,Ltd.

Country or region before: China

CB02 Change of applicant information